Boston Scientific Co. (NYSE:BSX) is Sivik Global Healthcare LLC's 3rd Largest Position

Sivik Global Healthcare LLC raised its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,000 shares of the medical equipment provider's stock after acquiring an additional 5,000 shares during the period. Boston Scientific makes up about 5.2% of Sivik Global Healthcare LLC's portfolio, making the stock its 3rd biggest holding. Sivik Global Healthcare LLC's holdings in Boston Scientific were worth $9,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in shares of Boston Scientific during the 3rd quarter worth $28,000. Dunhill Financial LLC grew its position in Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 152 shares during the last quarter. Global Wealth Strategies & Associates raised its stake in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC bought a new position in shares of Boston Scientific in the fourth quarter worth about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $30,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Up 0.9 %

Shares of BSX traded up $0.88 during trading hours on Monday, hitting $103.24. The stock had a trading volume of 3,893,024 shares, compared to its average volume of 5,785,270. The firm has a 50 day simple moving average of $93.47 and a 200-day simple moving average of $86.33. Boston Scientific Co. has a 1-year low of $64.08 and a 1-year high of $104.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a market capitalization of $152.16 billion, a P/E ratio of 85.38, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company's stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BSX. Raymond James increased their price objective on shares of Boston Scientific from $101.00 to $119.00 and gave the company a "strong-buy" rating in a research note on Friday. Truist Financial boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. TD Cowen increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a report on Monday, December 16th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Buy" and a consensus target price of $100.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.